It won't be entirely shorters. It will be some people 'taking risk off' ahead of the 14 days on the BLA resubmission.
Quite why they would do that below the levels prior to this announcement, defeats me. Happy to take the other side to that at these levels.
MSB certainly had poor luck in 2020/21 (and management not without fault either), to get zero for four. They've done their FDA homework on the GVHD BLA resubmission and clearly done it with CLBP, or they would not have been granted a RMAT. Happy to have a flutter on that.
Ann: FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP, page-124
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.020(1.78%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.13 | $1.09 | $4.556M | 4.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9590 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 3132 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |